Vaxcyte announces pricing of public offerings and $500 million convertible notes due 2032
PCVX•Vaxcyte priced public offerings of common stock and pre-funded warrants at $64 each, with a $0.001 warrant exercise price, and announced $500 million of convertible notes due 2032.
1. Offering terms
Vaxcyte announced pricing of concurrent public offerings of common stock and pre-funded warrants, alongside $500 million of convertible senior notes due 2032. The common stock and pre-funded warrants were offered at $64 each; the warrants have an exercise price of $0.001.
